Opens in a new tab

EOFlow v Insulet (CoA, 4 February 2026)

Date4 February 2026
CourtCoA
DivisionLuxembourg (LU)
Type of actionAppeal RoP220.2
Case number(s)UPC_CoA_930/2025
Registry referenceUPC_CoA_930/2025
PartiesEOFlow Co., Ltd. v. Insulet Corporation

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

The Court of Appeal holds inadmissible the appeal by EOFlow Co., Ltd. against the order of the Milan Central Division of 4 December 2025 (UPC_CFI_1167/2025), which, at the request of Insulet Corporation, had imposed penalty payments of EUR 150,000 for non-compliance with the provisional measures ordered by the Court of Appeal on 30 April 2025 on EP 4 201 327, together with EUR 10,000 in costs. The order confirms that an order imposing penalty payments may be appealed only with leave, and that leave must be granted expressly.

Question

May a first instance order imposing penalty payments, and deciding on the costs of those proceedings, be appealed without leave?

Decision

An order imposing penalty payments falls neither under Art. 73(2)(a) UPCA nor under Rule 220.1(c) RoP, Rule 354.4 RoP merely clarifies this, and an appeal requires leave (paragraphs 16 to 19). The Milan Central Division had expressly granted leave on the confidentiality issue but only noted that the penalty was subject to appeal. Leave cannot be presumed (paragraphs 20 to 22). Since no leave was sought, discretionary review under Rule 220.3 RoP is not available (paragraphs 23 and 24). A cost order deciding both who bears the costs and their amount follows the remedy against the main decision, Rule 221 RoP covering only disputes on the amount (paragraph 29). The appeal is dismissed as inadmissible, and the application for suspensive effect fails with it (paragraphs 31 to 33). EOFlow may, within 14 days, cure its appeal on the dismissal of its confidentiality requests, which did not state the order sought (paragraph 34).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 73(2)(a) and (b) and 82(4)
Rules of Procedure
Rules 157, 220, 221, 223, 229.1 and 354.4
Case law cited
Insulet v EOFlow, Court of Appeal, 30 April 2025 (UPC_CoA_768/2024), Suinno v Microsoft, Court of Appeal, 9 October 2024, UPC_CoA_586/2024, Photon Wave v Seoul Viosys, Court of Appeal, 15 October 2024, PC 01/2024, Ballinno v Kinexon, Court of Appeal, 12 May 2025, UPC_CoA_328/2024, Total v Texas Instruments, Court of Appeal, 14 January 2025, UPC_CoA_651/2024, Amazon v InterDigital, Court of Appeal, 29 December 2025 (UPC_CoA_936/2025).

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CoA_930/2025 official number

Follow this case

First instance cited in the decision: UPC_CFI_1167/2025

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 4 December 2025 Insulet v EOFLOW (CFI, 4 December 2025) Application RoP262A · UPC_CFI_1167/2025

    The Milan Central Division ordered EOFLOW to pay a penalty of EUR 150,000 for violating the preliminary injunction granted by the Court of Appeal on 30 April 2025, on the basis of evidence that EOFLOW had exported 11,520 insulin pump devices to Italy and Sweden between May and July 2025 in breach of that injunction, an…

  2. 29 January 2026 EOFlow v Insulet (CoA, 29 January 2026) Application RoP262.2 · UPC_CoA_930/2025

    Les pièces déposées comme confidentielles sont rendues accessibles à l’autre partie et la demande de restriction d’usage est rejetée : les informations communiquées en exécution d’une injonction ne sont protégées que par une demande au titre de la règle 262A.

  3. 4 February 2026 EOFlow v Insulet (CoA, 4 February 2026) Appeal RoP220.2 · UPC_CoA_930/2025 · appeal, first-instance number cited in the decision
  4. 18 March 2026 EOFLOW v Insulet (CoA, 18 March 2026) Appeal RoP220.2 · UPC_CoA_930/2025 · appeal, first-instance number cited in the decision

    La cour d'appel rejette l'appel d'EOFlow : les informations communiquées à Insulet sans ordonnance au titre de la règle 262A ne sont plus des secrets d'affaires ni des informations confidentielles, aucune limitation implicite d'usage n'existant.

What the record states

Nature of the act
Appeal RoP220.2
Outcome (Dhenne Avocats summary)
L’appel contre l’ordonnance prononçant une astreinte et fixant les frais est irrecevable faute d’autorisation expresse de la division de première instance. La demande d’effet suspensif est rejetée.
Appeal
Decision of the Court of Appeal (first instance cited: UPC_CFI_1167/2025).
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.